Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
The U.S. Food and Drug Administration (US FDA) concluded its inspection of Concord Biotech's Valthera Formulation Facility with one minor procedural observation. This was announced on September 18, 2026.
Over the last five years, Concord Biotech has shown a compounded sales growth of 11% and a compounded profit growth of 1%. However, for the Trailing Twelve Months (TTM), compounded sales growth was -6% and compounded profit growth was -20%.
As of March 2020, Concord Biotech reported Total Assets of ₹941 crore and Total Liabilities of ₹941 crore. This compares to ₹763 crore in Total Assets and ₹763 crore in Total Liabilities as of March 2019. Reserves stood at ₹761 crore in March 2020, up from ₹673 crore in March 2019. Borrowings increased significantly to ₹52 crore in March 2020 from ₹9 crore in March 2019, and CWIP rose to ₹141 crore from ₹19 crore over the same period.
For the fiscal year ending March 2025, Concord Biotech is projected to have Cash from Operating Activity of ₹245.0 crore and Free Cash Flow of ₹134.0 crore. For the fiscal year ending March 2026, these figures are projected to be ₹264.0 crore for Cash from Operating Activity and ₹169.0 crore for Free Cash Flow. Net Cash Flow is projected at -₹14.0 crore for March 2025 and ₹7.0 crore for March 2026. Cash from Financing Activity is expected to be -₹99.0 crore and -₹115.0 crore for March 2025 and March 2026, respectively.
On a daily timeframe as of September 18, 2026, the Supertrend indicator suggests a bearish direction, with the closing price of ₹1494.4 being above the 20-day Exponential Moving Average (EMA) of ₹1468.4. On a weekly timeframe, the Supertrend indicator shows a bullish direction, with the closing price of ₹1494.4 above the 20-week EMA of ₹1364.86.
As of 18 Sept 2026, 03:30 pm
Showing 3 of 14 candles
Recent drawdown or price variability is materially high and may lead to larger short-term outcomes.
Primary driver: Price remains materially below a previous peak
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹257.49 crore | PEAK₹326.08 crore | ₹277.77 crore | ₹247.06 crore | ₹203.99 crore |
| Profit Before Tax | ₹77.07 crore | PEAK₹114.25 crore | ₹86.85 crore | ₹83.39 crore | ₹57.24 crore |
| Profit Loss For Period | ₹57.70 crore | PEAK₹88.47 crore | ₹63.64 crore | ₹63.06 crore | ₹44.06 crore |
| Tax Expense | ₹20.65 crore | PEAK₹25.61 crore | ₹22.51 crore | ₹22.62 crore | ₹14.67 crore |
| Finance Costs | ₹3.64 lakh | PEAK₹8.40 lakh | ₹8.15 lakh | ₹5.91 lakh | ₹5.86 lakh |
In the quarter ended 30 June 2026, Concord Biotech Limited’s revenue and profit fell from the record levels of the March 2026 quarter. Compared to the same quarter a year ago, however, both revenue and profit grew substantially. Profit margins expanded modestly, and other income added ₹12.83 crore to earnings.
Other income for the quarter was ₹12.83 crore. The income statement also includes a share of profit from associates and joint ventures of ₹1.28 crore. This line item appears for the first time in the reported periods and is presented after tax expense. Its inclusion means that net profit (₹57.70 crore) is ₹1.28 crore higher than profit before tax (₹77.07 crore) minus tax expense (₹20.65 crore).
Concord Biotech’s June 2026 quarter saw revenue and profit decline from the record levels of the March 2026 quarter, but both remained significantly higher than the June 2025 quarter. Profit margins improved modestly year-on-year, and other income contributed ₹12.83 crore. A new line item for share of profit from associates added ₹1.28 crore to net profit.
Exchange disclosures and regulatory announcements for Concord Biotech.
Intimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II Valthera Formulation Facility of the Company |SUBJECT: General Updates
Concord Biotech Limited announced on September 17, 2026, that its officials will meet with JP Morgan Healthcare Group investors and analysts in Ahmedabad on September 23, 2026, at 12:30 pm. The meeting is scheduled to discuss only publicly available information, with no unpublished price sensitive information (UPSI) intended for disclosure. The company noted that the schedule may be subject to change due to exigencies.
Concord Biotech Limited officials will attend an investor conference organized by Phillip Capital PCG on August 26, 2026, from 1:00 PM to 3:00 PM IST in Ahmedabad, with discussions limited to publicly available information and no unpublished price sensitive information intended to be shared.
Concord Biotech reported Q1 FY27 revenue of INR257 crores, a 26% year-on-year increase, with API revenue growing 42% to INR219 crores and export revenue up 46%. EBITDA was INR82 crores (32% margin), and PAT was INR58 crores (22.4% margin). The company received U.S. FDA ANDA approvals for mycophenolate mofetil and tofacitinib tablets, and its injectable facility and Stellon Biotech U.S. distribution platform began commercial operations. Management guided for long-term revenue potential of INR3,000 crores (INR2,200-2,300 crores from API, INR600-700 crores from formulations) over 5-6 years, with capacity utilization at Unit 1 at 80%, Unit 3 at 55%, and Unit 2 at 25%.
Concord Biotech Limited successfully conducted its earnings call for the first quarter ended June 30, 2026, on August 3, 2026. The audio recording of this call, which discussed the unaudited financial results, is now available on the company's website.
Concord Biotech Limited has released its investor presentation for the first quarter ended June 30, 2026, detailing unaudited standalone and consolidated financial results. The company reported a 26% year-on-year revenue growth in Q1FY27, with export revenue increasing by 46%. Key highlights include USFDA approvals for Mycophenolate Mofetil & Tofacitinib Tablets, successful regulatory inspections by ANVISA, PPB Kenya, and NDA Uganda, and receiving an EcoVadis Silver Medal for sustainability. Consolidated revenue was Rs. 257 Crs, EBITDA Rs. 82 Crs, and PAT Rs. 58 Crs for Q1FY27.
Concord Biotech Limited published its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, on August 1, 2026. These results were reviewed by the Audit Committee and approved by the Board of Directors on July 31, 2026. The financial results have also been uploaded to the company's website in compliance with listing regulations.
Concord Biotech Limited held its 41st Annual General Meeting on July 31, 2026, where all six resolutions, including the adoption of financial statements, declaration of dividend, appointment of directors, and approval of loan limits to subsidiaries, were passed with the requisite majority. The voting results and the scrutinizer's report were submitted on August 1, 2026.
Recent market and company developments associated with Concord Biotech.
The key equity benchmarks ended mixed on Friday, as easing crude oil prices and softer global bond yields supported investor sentiment. Market sentiment was also aided by Moody's upward revision of India's FY27 GDP growth forecast to 7% from 6%, citing stronger-than-expected domestic activity and the resilience of the economy amid the ongoing conflict in West Asia. However, Moody's flagged elevated energy prices and El Ni-related food price pressures as risks to inflation, consumption and growth.
In the primary market, the NSE IPO was fully subscribed, while investors continued to track subscription trends in other ongoing issues and monitor the listing performance of recently listed companies.
The benchmark indices traded near the day's high in afternoon trade, supported by easing crude oil prices and softer global bond yields. Market sentiment also received a boost after Moodys raised its India FY27 GDP growth forecast to 7%, citing the resilience of the domestic economy despite ongoing geopolitical tensions in West Asia. The Nifty regained the 23,300 mark.
Concord Biotech said that the U.S. Food and Drug Administration (US FDA) had successfully concluded the inspection of the company's Valthera Formulation Facility, with one minor procedural observation.
Helios Mid Cap Fund, backed by Samir Arora, exited Dixon Technologies, Aadhar Housing Finance and Black Box in August. The fund added eight stocks, including Coforge and Lalithaa Jewellery, while increasing exposure to 15 stocks and holding 72 stocks across 23 sectors.
If grey market trends are anything to go by, the stock could make a strong debut with a premium of around 19% over its issue price. The grey market premium (GMP) currently stands at ₹185, indicating an estimated listing price of around ₹1,173 per share, compared with the IPO price of ₹988.
The employee reservation portion led with 1.19 times subscription; Retail Individual Investors subscription at 0.82 times, NII category is at 0.86 times. QIB remained the weakest segment at 0.35 times
Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity.
Comprehensive Section Breakdown for Concord Biotech
Strategic Vision: Biopharmaceutical company developing and manufacturing APIs and formulations.
• Over two and a half decades of experience in the biopharmaceutical industry.
• Leveraging advanced fermentation and semi-synthetic technologies.
• State-of-the-art manufacturing facilities meeting stringent international quality standards.
Revenue from operations was ₹257.49 crore in the June 2026 quarter, down 21% from ₹326.08 crore in the March 2026 quarter, but up 26% from ₹203.99 crore in the June 2025 quarter. Profit before tax followed a similar pattern: ₹77.07 crore, decreasing 33% from ₹114.25 crore in the prior quarter, but increasing 35% from ₹57.24 crore a year ago. Profit after tax was ₹57.70 crore, down 35% from ₹88.47 crore in the previous quarter, but up 31% from ₹44.06 crore in the same quarter last year.
The current quarter’s revenue is higher than each of the first three quarters of the previous fiscal year (₹203.99 crore, ₹247.06 crore, ₹277.77 crore) but lower than the fourth quarter. This aligns with the prior year’s quarterly progression, where revenue was lowest in the first quarter and highest in the fourth.
Material-related costs—comprising cost of materials consumed (₹69.85 crore), purchases of stock in trade (₹11.29 crore), and changes in inventories (a credit of ₹26.85 crore)—totaled a net of ₹54.29 crore, or 21% of revenue. Employee benefit expense was ₹43.64 crore (17% of revenue), and depreciation and amortization was ₹18.10 crore (7% of revenue). Finance costs remained negligible at ₹3.64 lakh.
Other income of ₹12.83 crore, equivalent to about 5% of revenue, added to earnings.
Profit before tax margin was 29.9% (₹77.07 crore / ₹257.49 crore), and profit after tax margin was 22.4% (₹57.70 crore / ₹257.49 crore). In the year-ago quarter, the corresponding margins were 28.1% and 21.6%, respectively, indicating a modest improvement in profitability.
Category: Manufacturing
The company manufactures niche and reliable APIs using fermentation and semi-synthetic methods, maintaining high-quality benchmarks. The API facility is dedicated to producing high-quality APIs.
Category: Manufacturing
Concord Biotech develops and manufactures niche formulations aimed at improving health outcomes for patients globally. This segment includes both global formulations and branded generic products for the Indian market.
Category: B2B Services
The company provides comprehensive Contract Development & Manufacturing Services, supported by technical expertise and adhering to global regulatory approvals.
Core Thesis: Leveraging advanced fermentation and semi-synthetic technologies across API and formulation development to serve global pharmaceutical needs.
• API Manufacturing: Production of niche and reliable APIs using fermentation and semi-synthetic methods with high-quality benchmarks. • Formulation Development: Development and manufacturing of niche formulations for global health outcomes, including branded generics for India. • CDMO Services: Providing comprehensive contract development and manufacturing services backed by technical expertise and global regulatory compliance.